Breyanzi access in Egypt: the EDA named-patient pathway

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

Quick orientation

Breyanzi (lisocabtagene maraleucel) is an autologous CD19-directed chimeric antigen receptor T-cell therapy approved by the US Food and Drug Administration in February 2021. The label has expanded across diffuse large B-cell lymphoma and other large B-cell lymphomas (initially third-line, then second-line after the TRANSFORM trial in June 2022), chronic lymphocytic leukemia and small lymphocytic lymphoma (March 2024), follicular lymphoma (May 2024), and mantle cell lymphoma (May 2024). The product is manufactured by Bristol-Myers Squibb. The pivotal TRANSCEND trials reported overall response rates of approximately 73 percent in large B-cell lymphoma with 53 percent complete response in heavily pretreated populations, and the safety profile shows lower rates of severe cytokine release syndrome than some earlier CD19 CAR-Ts. Breyanzi is not registered with the Egyptian Drug Authority (EDA), and access for an Egyptian patient runs through the personal-use import permit combined with autologous cell collection arranged at a CAR-T-authorised center.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

Why Egyptian patients ask about Breyanzi

Egypt has the largest tertiary oncology footprint in North Africa. The National Cancer Institute (NCI) at Cairo University, the 57357 Children's Cancer Hospital, the Naser Institute, Ain Shams University Specialized Hospital, Al-Salam International Hospital, As-Salam Specialised Hospital, Cairo University Hospitals (Kasr Alainy), Magrabi Cancer Centre, and the El-Gouna Hospital network all carry hematology-oncology programs. Several centers run autologous stem cell transplant programs that approach the operational complexity of CAR-T. Families arrive at the Breyanzi question after the conventional aggressive B-cell lymphoma sequence has been exhausted: R-CHOP or dose-adjusted EPOCH-R first-line, salvage with R-DHAP, R-ICE, or R-GDP followed by autologous stem cell transplant, and progressively more salvage with polatuzumab vedotin combinations, tafasitamab plus lenalidomide, or loncastuximab tesirine. For relapsed CLL, the conversation comes after BTK inhibitors and venetoclax-based combinations.

The EDA named-patient pathway for Breyanzi

Egypt's regulatory framework for unregistered-medicine import runs through the Egyptian Drug Authority (EDA) under Decree No. 425 of 2009 and subsequent EDA regulations. The personal-use import permit is available where an EDA-licensed physician documents the clinical necessity of a medicine not registered or not available in Egypt, and where no clinically equivalent locally registered alternative is suitable. For autologous CAR-T cell therapy, the EDA permit can issue in principle, with the operational complexity sitting in infusion-center identification and cell shipment chain of custody rather than in the regulatory paperwork.

A complete EDA application includes the clinical justification letter from the treating hematologist documenting the prior treatment course, refractory status, and CD19 CAR-T rationale; the treating physician's EDA medical license verification (Egyptian Medical Syndicate registration); the destination infusion center identification with FACT or equivalent CAR-T accreditation; the leukapheresis collection plan; the BMS manufacturing slot reservation; and the post-infusion monitoring plan with the local Egyptian hematologist. EDA processing for routine personal-use cases is typically 10 to 20 business days. CAR-T cases sit in an 8-to-16-week operational envelope.

Where Breyanzi cases are infused for Egyptian patients

Egypt does not currently operate a domestic CAR-T-authorised infusion center. Egyptian families pursuing Breyanzi typically infuse at a US academic medical center (MD Anderson, Memorial Sloan Kettering, Dana-Farber, City of Hope, Moffitt), a European reference center where compassionate-use access is available, or a regional Gulf CAR-T hub. King Faisal Specialist Hospital and Research Centre in Riyadh operates an established CAR-T program. Leukapheresis collection can be performed in Egypt at the NCI or a qualified Cairo center under chain-of-custody arrangements, with the apheresis product shipped to the BMS manufacturing facility.

Real cost picture for Breyanzi cases

US wholesale acquisition cost for Breyanzi is approximately USD 465,000 per dose. The all-in clinical envelope for an international CD19 CAR-T case typically runs USD 650,000 to USD 950,000 depending on infusion-center fee schedule, length of post-infusion stay, and whether complications require ICU support. The Egyptian pound trades at approximately 48 to 50 EGP to 1 USD, so the drug acquisition cost converts to approximately EGP 22.3 million to EGP 23.2 million at current rates. The all-in envelope sits in the EGP 31 million to EGP 47.5 million band. Cash-pay is the operating assumption; private insurance reimbursement of cross-border autologous CAR-T is not a routine line item in the Egyptian market.

Typical timeline for Breyanzi in Egypt

End-to-end, an Egyptian Breyanzi case typically runs 12 to 20 weeks from first physician contact to infusion-center discharge: clinical eligibility and infusion-center identification (weeks 1 to 3); EDA documentation and international travel logistics (weeks 3 to 6); leukapheresis collection and shipment to the US (weeks 6 to 7); BMS manufacturing window (weeks 7 to 12); patient travel and lymphodepleting chemotherapy (week 12 to 13); CAR-T infusion and post-infusion monitoring (weeks 13 to 16); discharge and return to Egypt (weeks 16 to 20). Manufacturing-failure rate of approximately 5 to 10 percent is a real operational risk.

What your physician needs to provide

For an Egyptian hematologist coordinating a Breyanzi case, the clinical justification letter documents the lymphoma subtype with cell-of-origin, MYC and BCL2/BCL6 status where relevant, the prior line-of-therapy summary, current disease burden including imaging, performance status, comorbidity profile, fitness for lymphodepleting chemotherapy, cardiac and pulmonary function, central nervous system status, and infection screening. The Breyanzi US prescribing information (BMS, FDA-approved label) requires baseline and serial monitoring for cytokine release syndrome and neurologic toxicities per the boxed warning.

Documentation set for the EDA filing

The full Egyptian Drug Authority personal-use import documentation set assembled for a Breyanzi case includes the prescription naming the specific patient, the product, the dose (single autologous infusion), and the manufacturing reference; the clinical justification letter from the treating Egyptian-licensed haematologist covering the items listed in the preceding section; the prescriber's Egyptian Medical Syndicate registration verification and EDA-recognised credential attestation; the destination infusion centre's FACT or JACIE accreditation certificate and the centre's signed acceptance of the named patient onto its CAR-T schedule; the leukapheresis collection facility licence and the chain-of-custody plan from the apheresis bag to the BMS manufacturing facility; the BMS apheresis manufacturing slot reservation document; the patient identity and travel-status documentation; and the financial readiness attestation, since CAR-T is cash-pay for Egyptian-resident families and the infusion centre will require funds on hand before scheduling. Reserve Meds packages the documentation kit, the prescribing haematologist signs the clinical components, and a registered Egyptian importer or the infusion centre's overseas-coordination office submits to the EDA.

Operational risk register for a Breyanzi case from Egypt

Four operational risks recur across cross-border CAR-T cases originating in Egypt. The first is disease progression during the manufacturing window. A patient whose disease accelerates during weeks 7 to 12 may require bridging therapy that the treating haematologist coordinates locally, and in a minority of cases the patient becomes ineligible for the planned CAR-T infusion. The bridging plan is set at the start of the case, not improvised mid-window. The second is manufacturing failure, which the BMS-published rate places at approximately 5 to 10 percent. The recovery plan typically requires re-apheresis, which extends the timeline by four to six weeks and depends on the patient's ongoing fitness. The third is post-infusion cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Both are managed by the receiving infusion centre under the manufacturer's REMS protocol; the role of the Egyptian-side team is to ensure long-term follow-up, including the 15-year follow-up commitment that CAR-T manufacturers require. The fourth is travel and visa logistics for the patient and one or two caregivers across the 12-to-20-week envelope, including the post-infusion 28-day stay within proximity of the infusion centre that the FDA label requires.

Insurance and funding posture

Reserve Meds operates on the assumption that an Egyptian Breyanzi case is cash-pay. Documented reimbursement for cross-border autologous CAR-T by Egyptian private health insurers (Misr Insurance, AXA Egypt, Bupa Egypt, Allianz Egypt, MetLife Egypt) is not a routine line item, and named-individual catastrophic-illness riders are case by case. Some Egyptian patient families combine personal savings with diaspora-family contribution and structured payment from corporate or private foundations. The Tahya Misr Fund and a small number of major Egyptian private foundations support oncology cases but typically below the USD 650,000 to USD 950,000 envelope of an international CAR-T. US manufacturer copay assistance and patient assistance programmes do not extend to cross-border patients. The financial scoping conversation happens at the start of the case, n